SCHEDULE 13G: Armistice Capital and Steven Boyd Disclose 9.99% Passive Stake in PDS Biotechnology Corp

Armistice Capital, LLC and Steven Boyd have jointly disclosed a passive beneficial ownership of 9.99% in PDS Biotechnology Corp's common stock as of March 31, 2025.

Summary

• Armistice Capital, LLC and Steven Boyd, collectively referred to as the "Reporting Persons," have filed a Schedule 13G.
• The filing indicates beneficial ownership of 4,547,925 shares of PDS Biotechnology Corp's common stock.
• This ownership represents 9.99% of the total outstanding common stock of PDS Biotechnology Corp.
• The shares are held with shared voting power and shared dispositive power by the Reporting Persons.
• Armistice Capital, LLC acts as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
• Steven Boyd is the managing member of Armistice Capital, LLC.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the disclosure of a significant institutional stake, which can be viewed favorably by the market, despite the filing being purely informational and passive.

Positives

• The disclosure of a significant 9.99% stake by an institutional investor like Armistice Capital may signal confidence in PDS Biotechnology Corp's long-term prospects.
• The passive nature of the investment, as certified by the filers, suggests no immediate intent to influence or change company control, which can provide stability.

Negatives

• The document does not contain information that would be considered negative regarding the company's operations or financial performance, as it is solely an ownership disclosure.

Risks

• The document explicitly states that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, mitigating immediate control-related risks from this specific filing.

Future Outlook

This Schedule 13G filing is a disclosure of current ownership and does not contain any forward-looking statements or guidance regarding PDS Biotechnology Corp's future operations or financial performance.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing indicates a significant passive investment by Armistice Capital, an investment firm, in PDS Biotechnology Corp. While the document itself does not provide broader industry trends, such an investment suggests that institutional capital continues to flow into the biotechnology sector, potentially reflecting investor interest in companies like PDS Biotechnology Corp.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may be viewed positively, potentially increasing investor confidence and liquidity in the stock.
• Company Management: Awareness of a large passive institutional holder may influence strategic decisions, though the filing explicitly states no intent to influence control.

Key Dates

Keywords

PDS Biotechnology Corp, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Passive Stake, SEC Filing, Biotechnology